Teon Therapeutics Announces FDA Acceptance of IND Application for Novel, Oral Immune Checkpoint Inhibitor, TT-816
SAN FRANCISCO--(BUSINESS WIRE)-- #CEO--Teon's novel oral cannabinoid CB2 receptor antagonist immune checkpoint inhibitor, TT-816, has IND accepted by FDA to begin Ph 1/2 clinical trial.
